A detailed history of Bridgeway Capital Management, LLC transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 192,856 shares of AQST stock, worth $595,925. This represents 0.02% of its overall portfolio holdings.

Number of Shares
192,856
Previous 192,856 -0.0%
Holding current value
$595,925
Previous $501,000 91.62%
% of portfolio
0.02%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.29 - $2.47 $58,050 - $111,150
45,000 Added 30.44%
192,856 $389,000
Q2 2023

Aug 14, 2023

BUY
$1.06 - $2.49 $5,194 - $12,201
4,900 Added 3.43%
147,856 $243,000
Q3 2022

Nov 14, 2022

SELL
$0.63 - $1.73 $38,682 - $106,222
-61,400 Reduced 30.05%
142,956 $167,000
Q2 2022

Aug 15, 2022

SELL
$0.64 - $2.57 $41,088 - $164,994
-64,200 Reduced 23.91%
204,356 $131,000
Q1 2022

May 16, 2022

BUY
$2.28 - $4.26 $195,067 - $364,468
85,556 Added 46.75%
268,556 $701,000
Q3 2021

Nov 15, 2021

BUY
$3.25 - $4.66 $182,000 - $260,960
56,000 Added 44.09%
183,000 $798,000
Q2 2021

Aug 16, 2021

SELL
$3.29 - $5.21 $82,250 - $130,250
-25,000 Reduced 16.45%
127,000 $504,000
Q4 2020

Feb 16, 2021

BUY
$4.65 - $7.79 $153,915 - $257,849
33,100 Added 27.84%
152,000 $813,000
Q3 2020

Nov 16, 2020

BUY
$4.12 - $9.09 $158,208 - $349,056
38,400 Added 47.7%
118,900 $577,000
Q1 2020

May 15, 2020

BUY
$1.54 - $6.75 $8,470 - $37,125
5,500 Added 7.33%
80,500 $176,000
Q4 2019

Feb 14, 2020

BUY
$3.06 - $8.78 $45,900 - $131,700
15,000 Added 25.0%
75,000 $437,000
Q2 2019

Aug 14, 2019

SELL
$3.72 - $6.95 $137,640 - $257,150
-37,000 Reduced 38.14%
60,000 $252,000
Q1 2019

May 15, 2019

BUY
$5.74 - $8.05 $556,780 - $780,850
97,000 New
97,000 $670,000

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $165M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.